BioNexus Gene Lab
BGLC
4 hedge funds and large institutions have $58.2K invested in BioNexus Gene Lab in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.
92% more capital invested
Capital invested by funds: $30.3K → $58.2K (+$28K)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
33% more funds holding
Funds holding: 3 → 4 (+1)
0.35% more ownership
Funds ownership: 0.37% → 0.73% (+0.35%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$37.5K |
| 2 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$5.83K |
| 3 |
SRL
Scientech Research LLC
Jersey City,
New Jersey
|
+$4.67K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$13K |
| 2 |
HF
HRT Financial
New York
|
-$6K |
BGLC Hedge Fund Activity: Q3 2024 in Review
4 of the 6,979 institutional investors tracked by Wall St. Rank reported a position in BioNexus Gene Lab (BGLC) for Q3 2024, worth a combined $58.2K — up 92% from $30.3K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BGLC positions and 2 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $37.5K. The largest seller was Virtu Financial, exiting entirely with an estimated $13K sold.
- 4 institutional investors held BioNexus Gene Lab (BGLC) as of Q3 2024, up from 3 in Q2 2024.
- Funds reported $58.2K of BioNexus Gene Lab stock for Q3 2024, up 92% quarter-over-quarter.
- 3 funds opened new BioNexus Gene Lab positions in Q3 2024 and 2 closed out, a net change of +1 holder.
- The largest BioNexus Gene Lab buyer in Q3 2024 was UBS Group, an estimated $37.5K added.
- The largest BioNexus Gene Lab seller in Q3 2024 was Virtu Financial, an estimated $13K sold.
Based on aggregated 13F filings for Q3 2024.